KRRO NASDAQ
Korro Bio, Inc.
1W: +40.9%
1M: +39.9%
3M: +32.1%
YTD: +65.2%
1Y: -65.1%
3Y: +6.4%
5Y: -96.1%
$13.30
+1.28 (+10.65%)
After Hours: $13.84 (+0.54, +4.06%)
Weekly Expected Move ±17.9%
$8
$10
$12
$14
$16
Credit Risk of going bust: higher than 95% of companies Debt: 19.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.86 (down 94%), Korro Bio, Inc. would be worth roughly what it owes.
Total debt $42.2M against a stock market value of $177.0M.
Distance to default 0.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $21.1M (short-term plus half of long-term), stock volatility 179.6%; Altman Z'' -5.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.86 (down 94%), Korro Bio, Inc. would be worth roughly what it owes.
Total debt $42.2M against a stock market value of $177.0M.
Distance to default 0.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $21.1M (short-term plus half of long-term), stock volatility 179.6%; Altman Z'' -5.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$1.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$195.9M
52W Range5.2-42.7
Volume322,492
Avg Volume190,756
Beta2.36
Dividend—
Analyst Ratings
Company Info
CEORam Aiyar
Employees57
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-03
Websitekorrobio.com
60 First Street
Cambridge, MA 02141
US
Cambridge, MA 02141
US
781-315-4600
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Latest News
Korro Bio (NASDAQ:KRRO) Major Shareholder Lynx1 Capital Management Lp Buys 25,124 Shares of Stock
Korro Bio (NASDAQ:KRRO) Major Shareholder Lynx1 Capital Management Lp Acquires 52,175 Shares of Stock
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Moderate Buy” by Brokerages
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lynx1 Capital Manage | P-Purchase | 25,124 | $11.75 | 2026-10-26 |
| Lynx1 Capital Manage | P-Purchase | 2,510 | $12.11 | 2026-10-23 |
| Lynx1 Capital Manage | P-Purchase | 12,175 | $9.68 | 2026-10-22 |
| Lynx1 Capital Manage | P-Purchase | 40,000 | $11.04 | 2026-10-22 |
| FORMELA JEAN FRANCOI | S-Sale | 31,888 | $14.12 | 2026-09-14 |